Insider purchase
Absci Corp (NASDAQ:ABSI) Chief Innovation Officer Andreas Busch acquired 100,000 shares of the company's common stock on March 12, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were purchased at $2.29 each, producing a total reported outlay of $229,000. After the transaction, Busch is shown as directly owning 421,446 shares of Absci stock.
Share price context
The insider purchase was reported as the stock was changing hands at $2.50, trading close to its 52-week low of $2.01. Absci shares are down 31.5% year-to-date. An InvestingPro analysis cited in public materials states that the stock appears overvalued at its current level relative to InvestingPro's Fair Value estimate. The firm also notes that Absci carries more cash than debt on its balance sheet. InvestingPro Tips additionally call out the stock's high volatility; those tips are part of a broader set of more than 10 insights available to subscribers, including a Pro Research Report covering ABSI and over 1,400 other U.S. equities.
Recent company developments
Absci's third-quarter earnings update included interim Phase 1 data for its TL1A program, ABS-101, that the company characterized as disappointing. The reported data indicated half-life characteristics that did not match next-generation TL1A comparator profiles, prompting Absci to halt internal advancement of ABS-101. The company said it will pursue alternative indications and seek partnering opportunities for the program instead of continuing internal development.
Analyst reaction and leadership hire
Following the ABS-101 update, Morgan Stanley downgraded Absci from Overweight to Equalweight and lowered its price target from $5.80 to $4.32, citing increased risk and reduced visibility for near-term value creation. In other leadership news, Absci announced the appointment of Ransi Somaratne as Chief Medical Officer. Somaratne, who previously worked at Vertex Pharmaceuticals, is slated to lead clinical development across Absci's pipeline of AI-designed therapeutics, including programs such as ABS-201 for androgenetic alopecia and endometriosis.
Company positioning
Collectively, the insider purchase, clinical data outcomes, analyst downgrade and the CMO hire illustrate a company adjusting its near-term strategy while managing investor expectations. The insider transaction increases a senior executive's direct holding at a time when the stock is trading near multi-quarter lows and when external analysis highlights both valuation concerns and balance-sheet capacity.
Summary
Andreas Busch bought 100,000 Absci shares on March 12, 2026 for $229,000, bringing his direct holdings to 421,446 shares. The purchase occurs as Absci deals with disappointing Phase 1 results for ABS-101, a program pause, a Morgan Stanley downgrade and the hiring of a new Chief Medical Officer.